Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, November 5, 2026

Back to the front page

From X

@ActAccordingly

PAA Research on X

I'm short a little $CRWV. Obviously I'm not happy with the move today, but I listened to the @cnbc interview with the CEO and two things really made me feel better: 1) @jimcramer called it an "inflection point" and a day that will go down in history (thank you for your tireless service Jim) 2) The $CRWV CEO's stuttering and non-stuttering sequences really were quite revealing. I'm not trying to belittle someone's speech challenges. Public speaking is hard, but someone with some basic CIA interview skills training would have a field day with his 5-10 minute segment on CNBC, particularly when asked about margins, insider selling, and project delays. He struggled mightily there to get the words out, which is telling. Of course @CNBC clipped out most of those parts of the interview, but you can watch the rest here. https://t.co/ldWzhWZXlO
@KEDM_COM

KEDM.com on X

Stride’s $LRN CEO James Rhyu seems to be getting canned and will be replaced by old-timer Robert Knowling. Is the 71-year-old CEO the right person to run a company that’s struggling with tech implementations, or is he better suited to manage relations with school boards? To calm the markets, LRN pre-released earnings in line with expectations, but they failed to comment on enrollment figures, which spooked markets. This has been a volatile name. If they guide to a return to growth in Q1, this should re-rate from the 9x FCF it currently trades at. If for some reason enrollments decline because parents are holding a grudge after a year of tech issues, watch out below. Operating leverage is very strong here. Mr. Knowling’s contract includes a change-of-control provision.

Investor Letters

All letters

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

TWST $8B
Hunterbrook 4 clicks

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

VSH $3.6B
Cestrian Capital Research 3 clicks

Thursday Tailwinds #13: Nov 5, 2026

Florida marinas are 92% full as boat counts rise and permits constrain new supply, creating pricing power for existing operators such as…

SUI $14B
Trade Ideas Flow 6 clicks
CHWY · long

Chewy INC

Chewy (CHWY) is presented as a long opportunity after a prior 2022 short thesis played out.

CHWY $9.2B
Value Investors Club 6 clicks

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

AA $10BNKE $60B
Aurelion Research 4 clicks

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

CURB $3.6B
Real Assets, Real Value 5 clicks

Coupang: 3Q26 Business Recap

Coupang’s product-commerce growth rose 9% as data-leak effects fade, while management expects margins to return to pre-incident levels by…

CPNG $27B
Speedwell Memos 3 clicks

update on Gartner

Gartner’s growth has stalled after federal contract losses and cautious commercial spending, raising questions about its competitive…

IT $13B
scuttleblurb 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 75 of 279

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.